# A Phase 2 to Evaluate the Efficacy, Safety and Tolerability of Combinations of Bedaquiline, Moxifloxacin, PA-824 and Pyrazinamide in Adult Subjects With Drug-Sensitive or Multi Drug-Resistant Pulmonary Tuberculosis.

> **NCT02193776** · PHASE2 · COMPLETED · sponsor: **Global Alliance for TB Drug Development** · enrollment: 240 (actual)

## Conditions studied

- Tuberculosis

## Interventions

- **DRUG:** PA-824
- **DRUG:** bedaquiline
- **DRUG:** moxifloxacin
- **DRUG:** pyrazinamide
- **DRUG:** isoniazid, rifampicin, pyrazinamide and ethambutol combination tablet

## Key facts

- **NCT ID:** NCT02193776
- **Lead sponsor:** Global Alliance for TB Drug Development
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-10-23
- **Primary completion:** 2016-02-08
- **Final completion:** 2018-02-07
- **Target enrollment:** 240 (ACTUAL)
- **Last updated:** 2019-07-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02193776

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02193776, "A Phase 2 to Evaluate the Efficacy, Safety and Tolerability of Combinations of Bedaquiline, Moxifloxacin, PA-824 and Pyrazinamide in Adult Subjects With Drug-Sensitive or Multi Drug-Resistant Pulmonary Tuberculosis.". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT02193776. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*